Key Highlights
- Intraday market data showed the stock at USD 0.66, down 47.45%, on Tuesday, November 17, 2026, and no company announcement accounting for the decline was found.
- In the most recent 10-Q, covering the quarter ended June 30, 2026, cash and equivalents were USD 0.6 million, compared with USD 5.0 million at December 31, 2025.
- Second-quarter net Revenue of USD 7.6 million trailed the USD 9.9 million of a year earlier, while a USD 115.0 million net loss came mainly from Fair Value losses.
- About USD 83.0 million of obligations are short-term (calculated): USD 80.8 million of current Debt and USD 2.2 million of promissory notes, with noncurrent debt at nil.
A Sharp Intraday Drop With No Announced Trigger
In intraday screener data, Scilex Holding (NASDAQ:SCLX) changed hands at USD 0.66 on Tuesday, November 17, 2026, a 47.45% decline that serves as the figure of record. Company releases and filings were checked, and none dated November 14 to November 17 explains the move, so no cause is stated. The company markets pain products such as ZTlido, ELYXYB and GLOPERBA and is conducting a second Phase 3 study of SP-102 in sciatica, which started in September 2025. Because the shares trade below USD 1, a few trades can shift the price, spreads may be wide and quoted moves can reverse, so the drop should not be read as a trend.
The Latest 10-Q: USD 0.6 Million of Cash
The most recent filing is a 10-Q covering the second quarter, which ended June 30, 2026. Net revenue for the second quarter came in at USD 7.6 million, below USD 9.9 million a year earlier, though the six-month total grew to USD 16.3 million from USD 14.9 million. Fair value swings on derivatives, digital Assets and Equity method investments account for much of the USD 115.0 million quarterly loss and USD 160.6 million six-month loss, the filing says. Cash and equivalents stood at USD 0.6 million, with marketable securities of USD 15 thousand. The cover page reports 8,493,000 common shares outstanding for Scilex Holding (NASDAQ:SCLX) on August 10, 2026, and the count since then was not verified.
Short-Term Debt, the ACEA Transaction and Other Open Items
Current debt of USD 80.8 million and promissory notes of USD 2.2 million together make about USD 83.0 million (calculated), whereas noncurrent debt dropped to nil from USD 22.5 million at the end of 2025. That reclassification pushes obligations into the near term, which prompts refinancing and dilution questions when cash is scarce. On May 6, 2026 the company said its subsidiaries ACEA Therapeutics and ACEA Pharma had signed a stock Acquisition agreement with Nasdaq-listed Phoenix Asia Holdings, with the parties putting the value at USD 1.0 billion, paid in 100 million new shares priced at USD 10.00, and completion targeted for the end of the second quarter. Whether that happened was not verified. Holders of Scilex Holding (NASDAQ:SCLX) will want the next 10-Q, news of any financing and any exchange notice.
Where Things Stand
No verified catalyst is available, so fundamentals are all that can explain the 47.45% decline. As of June 30, 2026, Scilex Holding (NASDAQ:SCLX) held just USD 0.6 million of cash, against roughly USD 83.0 million in current debt and notes (calculated), after a quarter that produced a USD 115.0 million net loss. Tight Liquidity leaves the shares exposed to financing news, dilution and listing questions, and a quote below USD 1 can reverse quickly. Look next for the third-quarter report, a Capital raise, word on the ACEA transaction and any company comment about current trading.



_11_17_2026_19_45_07_327614.jpg)
_11_17_2026_18_59_44_560836.jpg)

Please wait processing your request...